Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 251 - 275 of 14810 in total

Temocillin

Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection.
Approved
Investigational
Matched Description: … Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection. …
Matched Categories: … Penicillins With Extended Spectrum …

Bictegravir

Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.
Approved
Investigational
Matched Description: … recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and ... It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. …
Matched Categories: … emtricitabine, tenofovir alafenamide and bictegravir …

Sutimlimab

Cold agglutinin disease (CAD) is a type of autoimmune hemolytic anemia (AIHA) in which autoantibodies directed against red blood cell surface antigens cause hemolysis at low (3-4°C) temperatures.[A245154,L40114] This cold subtype accounts for approximately 15-25% of all AIHA and is more common in the elderly.[A245159,L40114] In approximately 90% of cases,...
Approved
Investigational
Matched Description: … ], as well as targeting of the complement system with drugs like [eculizumab], an anti-C5 mAb, and [pegcetacoplan ... and Raynaud phenomenon. ... that ultimately leads to both intra- and extravascular hemolysis. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Lynestrenol

Lynestrenol is a progestin and prodrug of norethisterone.
Approved
Investigational
Matched Description: … Lynestrenol is a progestin and prodrug of [norethisterone]. …
Matched Categories: … Combination Contraceptives (with Estrogen and derivatives) ... lynestrenol and estrogen ... lynestrenol and estrogen ... lynestrenol and ethinylestradiol ... lynestrenol and ethinylestradiol …

Sotalol

Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening...
Approved
Matched Description: … injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm ... [L6334] A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous …
Matched Categories: … Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index ... sotalol and thiazides ... Beta Blocking Agents and Thiazides ... sotalol and acetylsalicylic acid ... Beta Blocking Agents, Non-Selective, and Thiazides …

Dabrafenib

Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib),...
Approved
Investigational
Matched Description: … Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK ... It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. ... [L41955] It was also used for metastatic non-small cell lung cancer with the same mutation. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index …

Doxercalciferol

Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment...
Approved
Matched Description: … Doxercalciferol is marketed under the brand name Hectoral by Genzyme Corporation, and is manufactured ... Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic ... kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients with …
Matched Categories: … Diet, Food, and Nutrition ... Vitamin D and Analogues ... Sex Hormones and Insulins …

Flavone

Approved
Experimental

Dihydro-alpha-ergocryptine

Alpha-dihydroergocryptine is usually referred to the mixture of the alpha and beta dihydroergocryptine. These two compounds are differentiated in the position of a methyl group. This structural difference is due to a proteinogenic amino acid replacement from leucine to isoleucine. Both compounds are hydrogenated ergot derivatives. Alpha-dihydroergocryptine approved drug product...
Approved
Matched Description: … Alpha-dihydroergocryptine is usually referred to the mixture of the alpha and beta dihydroergocryptine …

Drostanolone propionate

Approved
Illicit
Matched Categories: … Testosterone and derivatives …

Cabotegravir

Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine.[A227668,L31188,L31193] Early research into cabotegravir showed it had lower oral bioavailability than dolutegravir, which resulted in the development of long acting monthly intramuscular injection formulation for cabotegravir.[A227668,L31193] Cabotegravir was granted FDA approval on...
Approved
Investigational
Matched Description: … combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and ... Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside ... [A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine …

Flutamide

An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Approved
Investigational
Matched Description: … An antiandrogen with about the same potency as cyproterone in rodent and canine species. …
Matched Categories: … Hormone Antagonists and Related Agents ... Antineoplastic and Immunomodulating Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Etelcalcetide

Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.
Approved
Investigational
Matched Description: … approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with …
Matched Categories: … Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins …

Busulfan

Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought...
Approved
Investigational
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Bilastine

Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.
Approved
Investigational
Matched Description: … new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and …
Matched Categories: … Decongestants and Antiallergics …

Mirikizumab

Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis. It inhibits the actions of interleukin-23 (IL-23), a pro-inflammatory cytokine that activates pathways contributing to the development of inflammatory diseases.[L46237,L46257] Mirikizumab is approved in Japan and received a positive opinion from the EMA's Committee for Medicinal...
Approved
Investigational
Matched Description: … [L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and ... was eventually approved in the US in October 2023[L48651] for the treatment of adult patients with moderate-to-severely ... [L46237,L46257] Mirikizumab is approved in Japan[L46252] and received a positive opinion from the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Carbenicillin

Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.
Approved
Investigational
Matched Description: … It is susceptible to gastric juice and penicillinase and may damage platelet function. …
Matched Categories: … Penicillins With Extended Spectrum …

Micronomicin

Micronomicin is an aminoglycoside antibiotic which is marketed in Japan, and sold under the brand names Sagamicin and Luxomicina.
Approved
Matched Description: … Sagamicin and Luxomicina. ... Micronomicin is an aminoglycoside antibiotic which is marketed in Japan, and sold under the brand names …
Matched Categories: … Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index …

Pivmecillinam

Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin. [PubChem]
Approved
Matched Description: … It is active against gram-negative organisms and used as for amdinocillin. [PubChem] …
Matched Categories: … Penicillins With Extended Spectrum …

Norgestimate

Norgestimate was first described in the literature in 1977. It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. It is commonly formulated with ethinylestradiol as a combined oral contraceptive that can also be used to treat moderate acne...
Approved
Investigational
Matched Description: … [A191068] It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can ... developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with …
Matched Mixtures name: … Norgestimate and Ethinyl Estradiol ... Norgestimate and Ethinyl Estradiol ... Norgestimate and Ethinyl Estradiol …
Matched Categories: … Combination Contraceptives (with Estrogen and derivatives) ... norgestimate and estrogen ... norgestimate and ethinylestradiol ... norgestimate and ethinylestradiol ... Genito Urinary System and Sex Hormones …

Oxycodone

Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone...
Approved
Illicit
Investigational
Matched Description: … [A178696] It is currently indicated as an immediate release product for moderate to severe pain and as …
Matched Mixtures name: … Oxycodone and Aspirin ... Oxycodone and Aspirin ... Oxycodone and Acetaminophen …
Matched Categories: … Heterocyclic Compounds with 4 or More Rings ... oxycodone and naloxone ... oxycodone and ibuprofen ... oxycodone and naltrexone ... oxycodone and paracetamol …

Ribostamycin

Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization's critically important antimicrobials.
Approved
Experimental
Matched Categories: … Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index …

Ethotoin

Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread...
Approved
Matched Description: … Ethotoin is a hydantoin derivative and anticonvulsant. ... The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent …

Ursodeoxycholic acid

Ursodeoxycholic acid (UDCA), also known as ursodiol, is a naturally-occurring bile acid that constitutes a minor fraction of the human bile acid pool.[A256272,A256277] UDCA has been used to treat liver disease for decades: its first use in traditional medicine dates back more than a hundred years.[A256267,A256463] UDCA was first characterized...
Approved
Investigational
Matched Description: … [A256267,A256463] UDCA was first characterized in the bile of the Chinese black bear and is formed by ... [A256272] UDCA was first approved by the FDA in 1987 for dissolution of gallstones and for primary …
Matched Categories: … Bile Acids and Salts ... Bile and Liver Therapy ... Bile acids and derivatives ... Alimentary Tract and Metabolism ... Cholagogues and Choleretics …

Vandetanib

Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Approved
Matched Description: … with the potential for use in a broad range of tumour types. ... Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Displaying drugs 251 - 275 of 14810 in total